TrueTear in Sjogren's Disease Patients

Inclusion Criteria: * Subjects with Sjögren's syndrome based on American-European Consensus Group (AECG) American College of Rheumatology (ACR), or American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) criteria * Baseline Schirmer score (with topical anesthesia) of ≤10 mm/5 min and retest value (during nasal stimulation with cotton swab) of at least 4 mm/5min higher than baseline value * Baseline Ocular Surface Disease Index® (OSDI) total score ≥13 * Age greater than or equal to 22 years old * Able to complete questionnaires independently * Willing to sign the informed consent and deemed capable of complying with the requirements of the study protocol Exclusion Criteria: * Use of any topical ophthalmic medication, including artificial tears, within 4 hours of either visit * Chronic or recurrent epistaxis, coagulation disorders or other conditions that, in the opinion of the investigator, may lead to clinically significant increased bleeding * Use of systemic anticoagulants * Nasal or sinus surgery including nasal cautery or significant trauma * Severely deviated septum * Cardiac demand pacemaker, implanted defibrillator or other implanted electronic device * Have an active implanted metallic or active implanted electronic device in the head, a cardiac demand pacemaker, or an implanted defibrillator * Known hypersensitivity to any of the procedural agents or materials in the study device that contact the nasal mucosa * Corneal transplant in either or both eyes * Participation in any clinical trial within 30 days of the Screening Visit * A woman who is pregnant, planning a pregnancy, or nursing at the Screening Visit